公开(公告)号：US20230139890A1

公开(公告)日：2023-05-04

申请号：US17912403

申请日：2021-03-18

申请人： GI INNOVATION, INC.

发明人： Myoung Ho JANG ,  Jae Chan PARK

IPC分类号： C07K14/55 ,  C07K14/705 ,  C12N15/63

摘要： The present invention relates to a fusion protein dimer comprising a modified IL-2 protein and a CD80 protein fragment or a variant thereof. The fusion protein comprising an IL-2 protein and a CD80 protein fragment or a variant thereof can not only activate immune cells owing to IL-2, but also effectively regulate Treg cells owing to CD80. Therefore, the fusion protein can efficiently attack cancer cells, and thus can be usefully employed for treatment of cancer or an infectious disease.

公开(公告)号：US20220403019A1

公开(公告)日：2022-12-22

申请号：US17780364

申请日：2020-11-27

申请人： GI INNOVATION, INC.

发明人： Myoung Ho JANG ,  Su Youn NAM ,  Young Jun KOH ,  Young-Gyu CHO

IPC分类号： C07K16/24 ,  A61P35/00 ,  A61K47/64 ,  C07K16/28 ,  C07K16/30

摘要： There is provided a pharmaceutical composition for preventing or treating cancer comprising, as active ingredients, a fusion protein dimer comprising an IL-2 protein or a variant thereof and a CD80 protein or a fragment thereof, and an immune checkpoint inhibitor. The fusion protein containing an CD80 fragment, an Fc domain of an immunoglobulin, and an IL-2 variant in an embodiment can activate immune cells such as natural killer cells as well as control the immune cell regulatory activity of regulatory T cells. In addition, the combined administration of the fusion protein and an immune checkpoint inhibitor such as Keytruda known as a PD-1 inhibitor can effectively inhibit cancer. Therefore, a pharmaceutical composition containing, as active ingredients, a fusion protein dimer comprising an IL-2 protein or a variant thereof and a CD80 protein or a fragment thereof, and an immune checkpoint inhibitor can be effectively applied to the treatment of cancer and has high industrial applicability.

公开(公告)号：US20220257693A1

公开(公告)日：2022-08-18

申请号：US17625668

申请日：2020-07-07

申请人： GI INNOVATION, INC.

发明人： Myoung Ho JANG ,  Bo-Gie YANG ,  Kyungwha LEE

IPC分类号： A61K38/00 ,  A61K9/00 ,  A61K9/70 ,  A23L33/18 ,  A61P37/08 ,  C07K14/735

摘要： A modified IgE Fc receptor having a high content of sialic acid and a pharmaceutical composition contains the modified IgE Fc receptor are disclosed. The polypeptide dimer having a high content of sialic acid not only has excellent safety and persistence in a body as compared with conventionally used anti-IgE antibodies, but also shows strong binding to IgE. Thus, the polypeptide has the advantage of an extended administration cycle. The polypeptide dimer is also an IgE single target substance, and unlike conventional anti-IgE antibodies to which the Fc of IgG1 is applied, does not bind to an Fc gamma receptor. The polypeptide dimer can be usefully used for the prevention or treatment of allergic diseases.